AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Adcetris' fourth-quarter sales in the U.S. and Canada came in below the Street's expectations and its third-quarter haul, Seattle Genetics reported.

Wednesday, the FDA approved Padcev, a first-of-its kind antibody-drug conjugate. The product targets Nectin-4, a protein on the surface of cells.